Aulitzky W E, Neubauer A, Kolbe K, Schneller F, Busemann C, Schleiermacher E, Peschel C, Siegert W, Huber C, Huhn D
IIIrd Department of Internal Medicine, Medical Center of the Johannes Gutenberg University, Mainz, Germany.
Bone Marrow Transplant. 1996 May;17 Suppl 3:S67-9.
Mobilization of Philadelphia chromosome (Ph) negative peripheral blood stem cells has been reported subsequent to intensive chemotherapy. We asked whether peripheral blood stem cells can be harvested subsequent to a less toxic chemotherapy regimen. Patients were treated with idarubicin 12 mg/m2 on day 1 and 2 and ara-C 100 mg/m2 days 1-5 and 5 or 10 micrograms/m2 G-CSF. In case of insufficient yield chemotherapy was repeated using IL-3 and G-CSF for mobilization of stem cells. Fourteen patients received 18 cycles of chemotherapy. The majority of patients were in late chronic phase and treated after secondary (interferon-alpha) IFN-alpha resistance. sufficient numbers of peripheral blood stem cells were harvested in 11 out of 14 patients. Although mixed Ph positive/Ph negative leukaphereses were harvested in the majority of patients, in no case were sufficient numbers of purely Ph negative progenitor cells for transplantation obtained. No toxic deaths were observed during the aplasia and the toxicity was acceptable. These preliminary results demonstrate that this procedure can be safely applied in patients with chronic phase CML and allows the harvesting of sufficient numbers of peripheral blood stem cells. The efficacy of this regimen for the mobilization of Ph negative cells should be further explored in patients at an earlier stage of the disease.
据报道,强化化疗后可动员出费城染色体(Ph)阴性的外周血干细胞。我们探讨了毒性较小的化疗方案后是否能够采集外周血干细胞。患者在第1天和第2天接受12 mg/m²的伊达比星治疗,第1 - 5天接受100 mg/m²的阿糖胞苷治疗,以及5或10μg/m²的粒细胞集落刺激因子(G-CSF)治疗。若采集量不足,则使用白细胞介素-3(IL-3)和G-CSF重复化疗以动员干细胞。14例患者接受了18个周期的化疗。大多数患者处于慢性期晚期,且在对干扰素-α(IFN-α)产生继发性耐药后接受治疗。14例患者中有11例采集到了足够数量的外周血干细胞。尽管大多数患者采集到的是Ph阳性/Ph阴性混合的白细胞成分,但均未获得足够数量的纯Ph阴性祖细胞用于移植。在再生障碍期未观察到毒性死亡,且毒性是可接受的。这些初步结果表明,该方法可安全应用于慢性粒细胞白血病(CML)慢性期患者,并能采集到足够数量的外周血干细胞。该方案动员Ph阴性细胞的疗效应在疾病早期患者中进一步探索。